Original Research
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions
Page: 5-13
Author byline as per print journal: Shon Crampton1, BA; Alla Polozova1, PhD; Darin Asbury2, BS; Alexis Lueras2, BS; Paul Breslin1, BS; Jane Hippenmeyer3, PharmD; Jennifer Litowski1, PhD; Monica Goss2, PhD… Read More »
Pharmacy chain drives choice among manufacturers of generic drugs in the US Medicare population
Author(s): 1 Steven Kozlowski, MD, 2 Ellen Tworkoski, MS, MPhil, 3 Carmen Dekmezian, MS, 4 Yanchang Zhang, MPH, 5 Natasha Flowers, BA, 6 Alvin So, MS, 7 Andreas M Schick, PhD, 8 Michael Wernecke, BA, 9 Thomas MaCurdy, PhD, Jeffrey A Kelman, MD, MMSc
Page: 98-106
Author byline as per print journal: Steven Kozlowski1, MD; Ellen Tworkoski2, MS, MPhil; Carmen Dekmezian2, MS; Yanchang Zhang2, MPH; Natasha Flowers2, BA; Alvin So3, MS; Andreas M Schick3, PhD; Michael… Read More »
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Author(s): Brian Godman, BSc, PhD, Steven Simoens, MSc, PhD
Page: 49-70
Author byline as per print journal: Brian Godman1,2,3,4, BSc, PhD; Andrew Hill5; Professor Steven Simoens6, MSc, PhD; Amanj Kurdi1,7, BSc, PhD; Jolanta Gulbinovič8, MD, PhD; Antony P Martin2,9; Angela Timoney1,10;… Read More »
Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications
Author(s): Amanj Kurdi, BSc, PhD, Axel Leporowski, MD, Brian Godman, BSc, PhD, Holly McCabe, MSc, Marion Bennie, MSc, Professor Alec Morton, PhD, Sean MacBride-Stewart, MSc, Simon Hurding, MD
Page: 142-51
Author byline as per print journal: Professor Brian Godman1,2,3, BSc, PhD; Amanj Kurdi1,4, PhD; Holly McCabe5, MSc; Sean MacBride-Stewart6, MSc; Axel Leporowski5, MD; Simon Hurding7, MD; Professor Marion Bennie1, MSc; Professor… Read More »
In vitro analytical and antibiotic comparison of generic moxifloxacin against E. coli and S. aureus bacteria strains
Author(s): Antistio Alviz-Amador, MSc, Jairo E Mercado Camargo, MSc, Marlene Duran-Lengua, MSc, PhD
Page: 121-6
Author byline as per print journal: Auxiliary Professor Antistio Alviz-Amador1, MSc, Pharmaceutical Chemist; Jairo E Mercado Camargo2, MSc; Marlene Duran-Lengua3, MSc, PhD, Bacteriologist Introduction: Moxifloxacin is a quinolone antibiotic often used to treat… Read More »
Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina
Author(s): 1 Francisco Fernández, MD, 2 Matías Deprati, MD, 3 Patricia Rodríguez Acedo, 4 Eduardo Spitzer, BSc, 5 Alvaro Romera, MD, 6 Nadia Español, BSc
Page: 111-20
Introduction and study objectives: Benefit-risk evaluations are essential throughout the life cycle of a drug to guarantee therapeutic efficacy for the authorized indications without an unacceptable incidence of adverse effects.… Read More »
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures
Author(s): Muriel Paul, PharmD, Professor Alain Astier, PharmD, PhD, Victoire Vieillard, PharmD
Page: 101-10
Author byline as per print journal: Victoire Vieillard, PharmD; Professor Alain Astier, PharmD, PhD; Muriel Paul, PharmD Objectives: This study assessed the long-term stability of the trastuzumab biosimilar CT-P6 (Herzuma®, Biogaran)… Read More »
Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
Author(s): Amy M DeLozier, MPH, Liza L Ilag, MD, Magaly Perez-Nieves, MPH, PhD, Puneet Kaushik, MPharm, Ran Duan, PhD, Robyn K Pollom, ANP, Samaneh Kabul, PharmD
Page: 56-62
Author byline as per print journal: Magaly Perez-Nieves1, MPH, PhD; Robyn K Pollom1, ANP; Ran Duan1, PhD; Samaneh Kabul1, PharmD; Amy M DeLozier1, MPH; Puneet Kaushik2, MPharm; Liza L Ilag1,… Read More »
Analysis of Drug Master Files registered in Japan: aiming for a stable supply of active pharmaceutical ingredients
Author(s): Maki Matsuhama, MSc, Ryosuke Kuribayashi, PhD
Page: 8-13
Introduction/Study objectives: A stable supply of active pharmaceutical ingredients (APIs) is indispensable for a stable supply of finished pharmaceutical products (FPPs). API manufacturers generally register API information as a Drug… Read More »
Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies
Author(s): Hannah Larkin, Judith Macdonald, Rebecca Lumsden, PhD
Page: 157-64
Introduction/Study objectives: Between March and May 2017, Pfizer conducted an internal global survey of 82 countries examining biosimilar pharmacy-mediated substitution to understand and benchmark the global policy landscape. Methods: Pfizer… Read More »